Cystic fibrosis findings by Hart, SL
Stephen Hart, Professor of Molecular Genetics at the 
University College London Institute of Child Health 
in the UK, shares his enthusiasm for new and vital 
research into gene-based therapies for cystic fibrosis
Respiratory disease is the main cause of 
premature death in cystic fibrosis (CF) 
patients, of which there are around 9,000 in 
the UK. What current treatments exist for 
this condition?
CF is caused by mutations in the gene 
encoding the cystic fibrosis transmembrane 
conductance regulator (CFTR), a cyclic 
AMP-activated chloride channel. The drug 
Kalydeco (Vertex Pharmaceuticals) restores 
the functionality of CFTR, but only in a rare 
group of patients with the G551D mutation. 
It was recently approved for clinical use and 
significantly improves lung function. However, 
for most patients the only treatment currently 
available is symptomatic relief. 
Our improved understanding of CF pathology, 
genetics and immunology, as well as new 
technologies, demonstrate that it is time for a 
re-evaluation of the potential of new CF gene 
therapy strategies.
In a previous study, your group 
demonstrated that a receptor-targeted 
nanocomplex – comprising targeting 
peptides, cationic liposomes and plasmid 
DNA – is highly effective for airway 
epithelial transfection in vitro and in vivo. 
Could you provide some insight into how 
this technique works?
The peptide component, through its amino acid 
sequence, contains two functional domains: 
one a lysine-rich, positively charged region that 
enables packaging of the negatively charged 
nucleic acids into nanoparticle structure; the 
other a receptor-targeting motif similar to 
the targeting molecules on rhinovirus, which 
infects lungs to cause colds. 
The peptide-targeting properties and net 
positive charge of the nanocomplexes 
enable binding and uptake into cells by 
endocytosis. Endosomal enzymes can 
destroy the DNA but the lipid components 
of the nanocomplexes enable fusion with 
the endosomal bilayer and escape into the 
cytoplasm and subsequently the nucleus. 
Thus, the combination of lipids and peptides 
endows the nanocomplexes with multiple 
functionalities that are essential for high 
overall transfection efficiency.
Why have you chosen to develop a CpG-free 
CFTR gene plasmid in a minicircle vector for 
gene therapy? 
Minicircles, expressing a codon-optimised, 
CpG-depleted CFTR, offer greater gene 
expression with lower immunogenic toxicity 
than conventional plasmid constructs. Plasmids 
contain elements that, although necessary for 
amplification in bacteria, are not required for 
gene expression in mammalian cells. These 
elements can be removed in minicircle DNA, 
reducing the size of the therapeutic molecule 
and increasing its potency.
Hypomethylated CpG motifs in plasmids 
occur more frequently in bacterial DNA 
than in eukaryotic genomes. Mammalian 
immune systems recognise unmethylated 
CpG motifs and induce an inflammatory 
response. This is highly undesirable, 
especially in CF lungs. Minicircles contain 
less CpG motifs and during gene synthesis 
most remaining CpG elements can be 
removed from the CF gene – CFTR – 
exploiting the redundancy of the genetic 
code to maintain the encoded protein 
sequence. Also during gene synthesis, codon 
optimisation can be performed to ensure 
highly efficient messenger RNA translation 
into protein, using codons for which transfer 
RNAs are most frequent. 
RNA interference is a technique for 
switching off gene expression. What would 
be the effect of silencing the epithelial 
sodium channel (ENaC)?
Loss of CFTR causes hyperactivity of ENaC 
leading to increased salt and water uptake 
from the watery, periciliary liquid (PCL) 
layer lining the lung; which is essential for 
normal ciliary clearance of particles, including 
bacteria, from the lung. Thus, dehydration 
of the PCL and mucus above the epithelial 
cells may be a major pathogenic mechanism 
in CF. Silencing the ENaC gene by small 
interfering RNA (siRNA) could reduce salt and 
water uptake, restoring hydration of the lung 
surface and so restoring normal mucociliary 
clearance. This could help to protect the 
lung from the frequent, damaging bacterial 
infections in the CF lung. 
Existing ENaC inhibitors are effective in 
reducing sodium uptake and restoring 
the PCL but their effects are too brief 
for practical benefit. How do you plan to 
improve this technique for CF treatment?
We aim to use siRNA which, once introduced 
and assembled into the enzymatic RNA-
induced silencing complex (RISC) in long-
lived epithelial cells, could potentially have a 
regulatory effect on ENaC for weeks before 
repeated administration is required.
Are there any new research developments 
that you think will have an impact on gene-
based CF therapies in the future?
New genome editing technologies such 
as the CRISPR/Cas9 system provide 
opportunities for correction of the specific 
CF mutation at the chromosomal level 
with a high degree of efficiency. Research 
suggests that this can be performed at all 
stages of development from stem cells 
to adult. Hence, I think that we may see 
genome editing gathering momentum in 
the coming years for CF gene therapy as 
well as many other diseases. Viral vectors 
also remain of interest, with research 
particularly active in lentiviral and adeno-
associated virus-based vectors.
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Genetic therapy, genuine relief
Cystic fibrosis is a debilitating, life-threatening disease for which the 
majority of treatment is limited to symptomatic relief, which can be 
extremely gruelling. Novel research is developing gene therapies with the 
potential to hugely ameliorate both life expectancy and quality of life
CYSTIC FIBROSIS (CF) is one of the most 
common autosomal recessive genetic disorders. 
It occurs in approximately one in every 2,000 
live births in the UK, and there are around 
60,000 people with the condition worldwide. CF 
was first described in the 1930s; the name refers 
to the scarring (fibrosis) and cysts observed 
within the pancreas of sufferers. It is caused 
by mutations in the gene encoding the cystic 
fibrosis transmembrane conductance regulator 
(CFTR), a cyclic AMP-activated chloride channel. 
The most severe effects of CF are in the lung, 
but the disorder also affects the pancreas, liver 
and intestines. It causes imbalanced water and 
ion movement across the epithelium of multiple 
organs which, in the periciliary liquid (PCL) 
layer of the lungs, produces a thick mucus. This 
is, in turn, associated with inflammation and 
bacterial infection, as well as life-threatening, 
progressive loss of lung function. Poor growth 
and infertility are other common symptoms, as 
are osteoporosis, liver problems, and ear, nose 
and throat disorders. 
LIMITED RELIEF
Symptomatic relief is, for most CF patients, 
the only treatment currently available. Such 
treatments are invasive, as Professor Stephen 
Hart, who is currently researching gene-based 
therapies for CF in the Institute of Child Heath 
at University College London, UK, explains: 
“Typically, patients require twice-daily regimens 
of physiotherapy and nebuliser treatments, 
supplemented with numerous orally delivered 
medications, often requiring more than three 
hours of treatment every day”.
There are also drug treatments, such as 
bronchodilators which relax the airways and 
improve breathing, antibiotics to treat bacterial 
infections, steroids to reduce inflammation 
and mucolytics such as deoxyribonuclease 
(DNase) which reduce the thickness of the 
mucus in the lungs, making it easier to clear 
during physiotherapy. However, it is evident 
that these treatments leave CF patients with a 
dramatically decreased quality of life. The hope 
of ameliorating the long-term health prospects 
and quality of life of CF patients, especially 
children, is what drives Hart’s search for an 
effective genetic therapy for the disease.
The trend towards symptomatic relief of CF has 
been influenced by unimpressive results from 
several genetic therapy trials in the 1990s. Since 
that time, many have been reluctant to pursue 
research in this area, but recent developments 
in small molecule drug therapies have rendered 
older liposome technologies and immunogenic 
viral vectors, with which these past trials were 
performed, obsolete.
A RETURN TO GENETICS
New technologies, such as nanoparticles, 
nucleic acids, nebulisation and imaging, are 
proving vital aids in the development of novel 
genetic therapy strategies. The success of 
the oral drug Kalydeco, developed by Vertex 
Pharmaceuticals and approved by the US Food 
and Drug Administration in early 2012, has 
demonstrated the potential of such therapies. 
Kalydeco is a small molecule drug which is 
genotype specific but not a nanoparticle or gene 
therapy. It has been effective in correcting CFTR 
activity, which is the same ultimate goal as 
gene therapy, hence providing proof of concept. 
However, Kalydeco is only able to target a very 
rare mutation found in approximately 4 per 
cent of CF sufferers. It is hoped that further 
research will produce a molecule which targets 
ΔF508, occuring in 90 per cent of CF individuals.
Despite the proven efficacy of such genotype-
specific therapies, their development and 
implementation may prove too expensive for 
UK National Health Service (NHS) provision. 
Thus, Hart’s current focus is on developing 
gene replacement and small interfering 
RNA (siRNA) therapies that will, 
in the long term, be far more 
cost-effective as they can be 
administered to all CF patients, 
regardless of genotype.
NEBULISATION OF 
NANOCOMPLEXES
Hart is currently 
investigating whether 
inactivation of the ENaC 
gene – which causes 
dehydration of the PCL 
and the often fatal build up 
of mucus in the lungs of CF 
patients – is able to protect 
CF lungs from bacterial 
infection. Treatment 
would be administered by 
nebulisation, most probably 
for the duration of the 
patient’s lifetime. There are 
challenges associated with 
this form of nanocomplex 
delivery; for instance, the 
output from the nebuliser 
relative to input and the 
size of aerosol particles 
produced by the nebuliser 
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will determine where in the lung the inhaled 
aerosol is deposited. In the CF lung, the target is 
the conducting airways. 
In a project funded by Sparks, a leading 
children’s medical research charity, Hart’s team 
demonstrated the importance of imaging CF 
lungs prior to and during the administration 
of the gene therapy vector. This allows the 
distribution of the vector in the lungs to be 
monitored. In humans, clinicians will be able to 
predict the level of efficacy of treatment, as this 
was shown to be altered by build up of mucus 
and obstruction in the lungs. After testing in vivo 
in pigs – a suitable animal model due to their 
comparable lung size – Hart’s team found the 
Trudell AeroEclipse* Breath Actuated Nebulizer 
to be best suited to their needs. Furthermore, 
histological and toxicological analyses reported 
no adverse affects from nebulisation. 
MURINE MODELS
Various studies were also carried out in the lungs 
of mice. “Experiments included instillation of 
nanocomplexes encoding luciferase or beta 
galactosidase reporter genes into murine lungs 
by the technique of oropharyngeal instillation,” 
outlines Hart. “Reporter gene expression 
was evaluated in homogenised lung extracts 
and in histological sections.” One important 
discovery from these trials was that repeat 
dosing of DNA maintained the same level 
effectiveness as the first dose. Furthermore, a 
single dose was persistent in expression for up 
to 21 days. Were this to be replicated in human 
lungs, the improvement to the quality of life of 
CF patients compared with currently available 
treatments is evident.
At present, Hart is working on further optimising 
CFTR transfection in the lungs of mice, for both 
single and repeat dosing. The aim is to improve 
the vector formulation composition: “We are 
investigating anionic nanocomplexes using 
anionic lipid components as opposed to the 
current cationic formulations, as well as surface 
modification strategies, such as PEGylation, 
both of which could help to improve penetration 
through mucus to better access the epithelia 
cell surface,” Hart explains. There will also be 
an improvement in vector formulation mixing 
through the use of microfluidic technologies, 
which facilitate the production of smaller, 
more consistent nanoparticles that can better 
penetrate mucus and therefore access the 
epithelial cell surface more effectively.
HUMAN IMPACT
Hart’s research is not limited to animal models. 
By collecting human normal and CF epithelial 
cells by nasal brushings and maintaining these 
cells on a semi-permeable membrane at an air-
liquid interface (ALI), a culture containing the 
full range of cell types can be developed. CF 
cells on an ALI display many of the same defects 
as CF lungs, even producing mucus. As the ALI 
allows the cells to be maintained over many 
weeks, they provide a valuable opportunity 
to learn more about the development of CF in 
humans and to test the efficacy of therapies at 
the cellular level. 
Results from this ongoing research could have 
life-changing and life-saving consequences 
for thousands of CF individuals. The proven 
success of Kalydeco has given both the medical 
establishment and health services cause to 
believe in the potential of gene-based therapy 
for the treatment of CF, thus Hart can hope 
that, once his therapies are fully developed, 
they will be granted the opportunity to have 
a real impact. 
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Cartoon of the nanoparticle formulation.
Transfection of cells showing differences in enhanced green fluorescent protein (eGFP) expression from plasmid 
(pMC) and mini-circle (MC).
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